Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Moleculin Biotech, Inc. MBRX

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — 3 —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
15.10
Revenue
—
Net Income
(30.33)
Free Cash Flow
(25.36)
Net Debt
(7.26)
Current Ratio
0.94
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
0.38
Past 5Y EPS Growth
26.36%
This Y EPS Growth
88.51%
Next Y EPS Growth
64.18%
Next 5Y EPS Growth
64.05%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 23.55 4.28 8.88 7.26
Receivables — — — —
Inventory — — — —
Other — — — —
26.27 5.19 9.69 8.72
2023 2024 2025 Q'26
Payables 6.82 5.36 6.85 9.31
ST’ Debt — — — —
Other — — — —
6.82 5.36 6.85 9.31
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (6.11) (6.66) — —
—
’25 (4.56) (5.58) (7.22) (5.37)
(22.73)
’24 (6.72) (5.95) (6.11) (5.08)
(23.86)
’23 (6.02) (5.13) (7.55) (4.90)
(23.59)
’22 (4.80) (8.00) (7.58) (7.26)
(27.64)
’21 (3.62) (6.78) (4.29) (4.26)
(18.95)
’20 (4.34) (4.93) (5.37) (3.12)
(17.77)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (6.11) (6.66) — —
—
’25 (4.56) (5.58) (7.22) (5.37)
(22.73)
’24 (6.72) (5.96) (6.11) (5.08)
(23.87)
’23 (6.02) (5.14) (7.58) (4.98)
(23.71)
’22 (4.81) (8.06) (7.58) (7.26)
(27.71)
’21 (3.62) (6.78) (4.29) (4.28)
(18.97)
’20 (4.34) (4.95) (5.71) (3.14)
(18.14)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (3.54) (1.40) — —
—
’25 (17.25) (12.25) (17.00) —
(28.42)
’24 (50.50) (42.50) (71.25) —
(158.00)
’23 (104.95) (74.96) (71.21) —
(376.75)
’22 (89.95) (89.95) (112.44) (89.95)
(378.56)
’21 (74.96) (56.22) (56.22) (33.73)
(221.14)
’20 (44.97) (382.23) (134.91) (0.23)
(659.67)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 306.38 126.75 37.50 3.13 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 768.75 618.75 393.75 91.25 — — —
High Price
‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 19 18 17 17 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — — — — — — ‡‡‡‡‡ — —
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — — — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (29.02) (29.77) (26.05) (33.56) — — —
EBT
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (29.02) (29.77) (26.05) (33.56) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.13 0.13 0.13 0.09 — — —
Depreciation
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (378.56) (376.75) (158.00) (28.42) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5,419.41) (298.62) (173.29) (19.19) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.14) (1.57) (0.09) 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5,432.55) (300.19) (173.38) (19.19) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10,233.53 330.04 81.39 12.67 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.08 0.14 1.18 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — — — ‡‡‡‡ — —
EV/Sales
— — — — — — — — — — — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (27.64) (23.59) (23.86) (22.73) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.07) (0.12) (0.01) — — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (27.71) (23.71) (23.87) (22.73) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.78 19.46 (0.16) 2.83 — — —
Working Cap'
‡‡‡‡‡ — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.45 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (42.69) (23.55) (4.28) (8.88) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.19 26.07 11.21 15.01 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.02%) (62.25%) (94.48%) (172.41%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (201.64%) (734.02%) (240.27%) (256.03%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (44.25%) (76.07%) (139.74%) (256.84%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Moleculin Biotech (MBRX), a clinical-stage oncology firm, is navigating a critical juncture with its lead candidate Annamycin, an anthracycline designed to treat acute myeloid leukemia (AML) while avoiding the cardiac toxicities of legacy therapies. After a decade of zero revenue, heavy R&D spending, and persistent cash burn—culminating in peak losses and significant share dilution that eroded book value per share by 97%—the company shows signs of stabilization, with 2024 losses narrowing 27% and net debt swinging back toward liquidity. Insider purchases by the CEO and CFO totaling $350,000 at sub-$0.40 levels signal confidence amid a lean operation of just 17-18 employees.

Pipeline progress, including FDA-cleared Phase 2/3 MIRACLE trial data expected in 2026, has de-risked early safety concerns and positioned MBRX for potential partnerships or approvals in a high-unmet-need AML market. Analyst projections forecast revenue ignition at $35.7 million in 2025—infinite growth from zero—followed by narrowing losses toward breakeven, with consensus price targets implying 361-614% upside from current depressed levels. While historical biotech patterns suggest rebound potential post-troughs, the 80% clinical failure rate, tight working capital, and ongoing free cash flow deficits underscore substantial downside risks before any transformative value materializes.

Read full commentary →

Moleculin Biotech, Inc. (MBRX) Latest News

News by impact score

Fine-tune

24 Aug

3 , 12:00 PM
Moleculin Biotech (MBRX) receives a Buy rating upgrade. Buy rating upgrade may lift short-term MBRX investor sentiment and trading activity.

14 Aug

3 , 8:30 AM
Moleculin Biotech released second quarter 2026 financial results and noted continued advancement of its pivotal MIRACLE Trial. Routine earnings release paired with standard trial progress offers moderate operational updates for the company.

31 Jul

4 , 8:10 AM
Moleculin’s MIRACLE R/R AML trial reports 37% blinded CRc rate in venetoclax-failed patients. Positive interim AML trial data can drive major gains in valuation and development momentum for the company.

3 , 10:12 AM
Moleculin Biotech prices $9.3 million public offering to raise capital. Public offering supplies operating capital while diluting shares and pressuring near-term stock price.

6 Jul

4 , 8:33 AM
Moleculin CEO Walter Klemp highlighted positive preliminary MIRACLE Trial results in a Virtual Investor "What This Means" segment. Positive preliminary MIRACLE Trial results indicate potential progress in Moleculin's key drug development program.

30 Jun

4 stocktwits.com, 2:52 PM
Moleculin Biotech's MBRX stock fell 25% after interim cancer trial data missed statistical significance. Negative trial results directly undermine Moleculin Biotech's core drug development pipeline and trigger sharp market selloff.

4 , 8:30 AM
Moleculin reports positive Phase 2/3 MIRACLE interim results showing Annamycin complete remission rates three times higher than control. Strong Phase 2/3 trial data with tripled remission rates signals major advance in drug development and market positioning.

5 Jun

4 GlobeNewswire, 8:29 AM
Independent market research shows strong physician intent to prescribe Moleculin's Annamycin for relapsed/refractory AML. Positive physician intent signals major potential adoption and revenue upside for Annamycin in AML.

4 Jun

3 GlobeNewswire, 8:31 AM
Moleculin Biotech CEO Walter Klemp highlighted enrollment of 45 subjects in the company's clinical trial during a Virtual Investor segment. 45-subject enrollment milestone signals clinical trial progress that may moderately influence investor views on development timelines.

29 May

4 GlobeNewswire, 8:21 AM
Moleculin Biotech presented ASCO 2026 data on Annamycin showing no detectable cardiotoxicity despite exposure levels far exceeding conventional anthracycline limits. Positive Annamycin safety data at major oncology conference strengthens drug development prospects and market positioning.

21 May

3 GlobeNewswire, 5:02 PM
Moleculin Biotech announced acceptance of its abstract for poster presentation at the 2026 ASCO Annual Meeting featuring cardiac safety data for Annamycin. Acceptance of ASCO poster on Annamycin cardiac safety data may moderately improve company visibility and investor sentiment without altering core operations.

15 May

4 GlobeNewswire, 8:30 AM
Moleculin Biotech, Inc. (MBRX) reported first quarter 2026 financial results and provided a clinical update on its pivotal MIRACLE trial. Financial results combined with a pivotal clinical trial update represent a major development likely to influence MBRX's trajectory and investor sentiment.

13 May

5 GlobeNewswire, 8:00 AM
Moleculin Biotech, Inc. (MBRX) announces imminent unblinding of the MIRACLE trial, as blinded data continue to significantly outperform historical benchmarks. Imminent unblinding of MIRACLE trial with blinded data outperforming benchmarks anticipates game-changing clinical success redefining MBRX's prospects.

4 Benzinga, 12:41 PM
Moleculin Biotech (MBRX), a nano-cap company, nears unblinding of key data from its leukemia trial. Approaching unblinding of key leukemia trial data poses a major catalyst for MBRX's stock volatility and pipeline validation.

12 May

4 GlobeNewswire, 9:30 AM
Cleveland Clinic's independent review finds no clinically significant cardiotoxicity from Moleculin's Annamycin in relapsed/refractory AML patients dosed beyond conventional anthracycline limits. Positive independent safety data addresses key cardiotoxicity risks for Annamycin, enhancing regulatory and clinical advancement prospects.

8 May

4 GlobeNewswire, 8:45 AM
Moleculin Biotech, Inc. (MBRX) secures an additional strategic patent for Annamycin, bolstering its global intellectual property protection and competitive positioning. Strategic patent acquisition strengthens IP for key drug Annamycin, enabling better global market defense and boosting long-term growth potential.

23 Apr

4 GlobeNewswire, 8:25 AM
Moleculin Biotech’s Annamycin extended survival by more than 60% in preclinical models of metastatic pancreatic cancer, with data presented at AACR 2026. Preclinical data demonstrating over 60% survival extension in metastatic pancreatic cancer significantly bolsters Annamycin's development prospects and MBRX investor sentiment.

7 Apr

3 GlobeNewswire, 8:36 AM
Moleculin Biotech, Inc. (MBRX) released the next CEO Corner segment highlighting Annamycin’s non-cardiotoxic profile as a key advantage. CEO spotlight on Annamycin's non-cardiotoxic profile strengthens product differentiation and investor sentiment without new clinical data.

23 Mar

4 GlobeNewswire, 8:31 AM
Moleculin Biotech, Inc. (MBRX) reaches 45-subject enrollment milestone in MIRACLE trial, triggering final countdown to mid-2026 data readout. 45-subject enrollment milestone advances MIRACLE trial toward mid-2026 readout, significantly boosting MBRX pipeline progress and investor outlook.

19 Mar

4 GlobeNewswire, 8:36 AM
Moleculin Biotech, Inc. (MBRX) reported full-year 2025 financial results and confirmed highly anticipated 45-patient interim data unblinding in pivotal MIRACLE trial remains on track for mid-2026. Confirmation of on-track interim data from pivotal MIRACLE trial signals major progress likely to significantly enhance investor sentiment and alter MBRX trajectory.

19 Feb

3 GlobeNewswire, 8:39 AM
Moleculin Biotech, Inc. (MBRX) announces exercise of warrants generating $8.3 million in gross proceeds. Warrant exercise infuses $8.3 million in cash, strengthening financial position for biotech operations amid funding needs.

18 Feb

4 GlobeNewswire, 8:20 AM
Moleculin Biotech's MIRACLE trial shows preliminary blinded complete response rate (CRc) of 40% in 30 patients. 40% preliminary blinded CRc rate in MIRACLE trial signals major clinical progress likely to drive significant positive market reaction for MBRX.

17 Feb

4 GlobeNewswire, 8:35 AM
Moleculin Biotech, Inc. (MBRX) announces Notice of Allowance from the Japanese Patent Office for a patent covering Annamycin, enhancing its intellectual property protection for the liposomal chemotherapy agent in Japan. Japanese patent allowance for Annamycin significantly strengthens MBRX's IP portfolio, supporting potential commercialization, partnerships, and market expansion in a major pharmaceutical market.

13 Feb

3 GlobeNewswire, 8:32 AM
Moleculin Biotech, Inc. has launched the CEO Corner platform to provide strategic insights and updates directly from its CEO, Walter Klemp. This initiative aims to enhance transparency and communication with stakeholders, offering a deeper understanding of the company's direction and initiatives. The platform will feature regular updates, discussions on strategic goals, and insights into the company's operations and market positioning. The launch of the CEO Corner platform is expected to moderately influence stakeholder engagement and market sentiment.

13 Jan

4 GlobeNewswire, 8:55 AM
Moleculin Biotech, Inc. announced that an independent assessment confirmed no cardiotoxicity associated with Annamycin in a study involving 90 subjects. This finding supports the safety profile of Annamycin, which is being developed as a treatment for various cancers, including relapsed or refractory acute myeloid leukemia. The results are expected to enhance the drug's potential in clinical applications and may positively influence investor confidence. Confirmation of no cardiotoxicity significantly enhances Annamycin's safety profile, likely impacting its market potential and investor sentiment.

12 Jan

4 GlobeNewswire, 8:36 AM
Moleculin Biotech, Inc. (MBRX) is advancing its clinical development plans with the first pivotal trial unblinding on schedule and expanding global trial efforts. The company is also pursuing multiple externally funded clinical programs, enhancing its outlook through 2026. The combination of pivotal trial progress and global expansion is likely to significantly impact the company's future performance and investor sentiment.

17 Dec

4 , 8:31 AM
Moleculin Biotech, Inc. announced positive results from a Phase 1 clinical trial of WP1066, a treatment for pediatric recurrent malignant brain tumors. The trial demonstrated safety and tolerability, with preliminary efficacy observed in some patients. These findings support further development of WP1066 as a potential therapeutic option for this challenging condition. Positive trial results could significantly enhance the company's product pipeline and investor sentiment.

10 Dec

4 GlobeNewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires, 8:30 AM
Moleculin Biotech, Inc. announced the exercise of warrants resulting in gross proceeds of $6.8 million. This capital infusion is expected to support the company's ongoing development of its drug candidates and enhance its financial position. The significant capital raised will likely bolster the company's strategic initiatives and investor confidence.

9 Dec

4 GlobeNewswire, 8:07 AM
Moleculin Biotech, Inc. has completed treatment for all 45 patients in its pivotal Phase 3 AML trial, known as the MIRACLE trial. The company is on track to report results in the first quarter of 2026, which could provide critical data on the efficacy of its treatment for acute myeloid leukemia. Completion of the pivotal trial positions the company for significant insights that could impact its market position and investor sentiment.

8 Dec

4 , 8:21 AM
Moleculin Biotech, Inc. has announced a new collaboration focused on the use of Annamycin for treating brain tumors. This partnership aims to explore the potential of Annamycin in addressing this challenging area of oncology, which could enhance the company's research and development efforts in cancer therapies. The collaboration represents a significant strategic move that could enhance Moleculin's position in the oncology market.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us